Bayer (FRA:BAYN) has been given a €123.00 ($143.02) target price by stock analysts at Baader Bank in a research note issued on Thursday, Borsen Zeitung reports. The firm currently has a “buy” rating on the healthcare company’s stock. Baader Bank’s price target indicates a potential upside of 77.31% from the stock’s current price.
Several other equities research analysts have also recently commented on the company. DZ Bank reissued a “neutral” rating on shares of Bayer in a report on Thursday, October 31st. JPMorgan Chase & Co. set a €69.00 ($80.23) target price on Bayer and gave the stock a “neutral” rating in a report on Monday, November 18th. Goldman Sachs Group set a €77.00 ($89.53) target price on Bayer and gave the stock a “buy” rating in a report on Monday, November 18th. HSBC set a €63.00 ($73.26) target price on Bayer and gave the stock a “neutral” rating in a report on Wednesday, November 27th. Finally, Bank of America set a €95.00 ($110.47) target price on Bayer and gave the stock a “buy” rating in a report on Friday, September 13th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and eight have issued a buy rating to the company. Bayer presently has a consensus rating of “Hold” and a consensus price target of €78.47 ($91.24).
Shares of FRA:BAYN opened at €69.37 ($80.66) on Thursday. Bayer has a 12 month low of €91.58 ($106.49) and a 12 month high of €123.82 ($143.98). The stock’s 50 day moving average price is €68.60 and its 200 day moving average price is €62.38.
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Further Reading: 52 Week Highs and Lows
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.